<DOC>
	<DOCNO>NCT00882518</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy quetiapine fumarate extended-release ( XR ) use mono-therapy , administer daily , treatment schizophrenic patient acute episode .</brief_summary>
	<brief_title>Efficacy Safety Quetiapine Fumarate Treatment Schizophrenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Chlorpromazine</mesh_term>
	<criteria>Schizophrenia diagnosis Provision write informed consent initiation study AIDS hepatitis B History seizure disorder Hospitalisation schizophrenic 1 month immediately enter study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Quetiapine Fumarate ( SEROQUEL ) Extended-Release ( XR )</keyword>
	<keyword>qualify PANSS assessment</keyword>
</DOC>